Biohaven Pharmaceutical Holding Company Ltd
NYSE:BHVN 3:59:56 PM EDT
| Market Cap (Intraday) | 8.67B |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $133.84 |
| 50-Day MA | $125.49 |
| 200-Day MA | $93.72 |
Biohaven Pharmaceutical Holding Company Ltd Stock, NYSE:BHVN
215 Church Street, New Haven, Connecticut 06510
Virgin Islands, British
Phone: +1.203.404.0410
Number of Employees: 825
Description
Biohaven Pharmaceutical Holding Co. Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of late-stage product candidates targeting neurological diseases, including rare disorders. It focuses on a pipeline of product candidates that represent mechanistic platforms, calcitonin gene-related peptide receptor antagonists, and glutamate modulators. The company was founded in September 2013 and is headquartered in New Haven, CT.